Cargando…

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery

PURPOSE: Bariatric surgery is nowadays commonly applied as treatment for morbid obesity (BMI > 40 kg/m(2)). As information about the effects of this procedure on a drug’s pharmacokinetics is limited, we aimed to evaluate the pharmacokinetics of CYP3A probe substrate midazolam after oral and intra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brill, Margreke J., van Rongen, Anne, van Dongen, Eric P., van Ramshorst, Bert, Hazebroek, Eric J., Darwich, Adam S., Rostami-Hodjegan, Amin, Knibbe, Catherijne A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628089/ https://www.ncbi.nlm.nih.gov/pubmed/26202517 http://dx.doi.org/10.1007/s11095-015-1752-9

Ejemplares similares

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
por: Brill, Margreke J. E., et al.
Publicado: (2014)

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
por: van Rongen, Anne, et al.
Publicado: (2017)

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
por: Brussee, Janneke M., et al.
Publicado: (2018)

First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
por: Brussee, Janneke M., et al.
Publicado: (2018)

Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
por: van Rongen, Anne, et al.
Publicado: (2016)

Does Weight Impact Anidulafungin Pharmacokinetics?
por: Lempers, Vincent J., et al.
Publicado: (2016)

Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
por: de Hoogd, Sjoerd, et al.
Publicado: (2017)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients
por: Smit, Cornelis, et al.
Publicado: (2019)

Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints
por: Blussé van Oud-Alblas, Heleen J., et al.
Publicado: (2019)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals
por: Smit, Cornelis, et al.
Publicado: (2020)

An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children
por: Diepstraten, J, et al.
Publicado: (2013)

Dose‐linearity of the pharmacokinetics of an intravenous [(14)C]midazolam microdose in children
por: van Groen, Bianca D., et al.
Publicado: (2019)

Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study
por: van Rhee, Koen P., et al.
Publicado: (2022)

The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
por: van Groen, Bianca D., et al.
Publicado: (2020)

Predicting CYP3A‐mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure
por: Brussee, Janneke M., et al.
Publicado: (2017)

The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study
por: Cristea, Sînziana, et al.
Publicado: (2020)

Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model
por: Völler, Swantje, et al.
Publicado: (2019)

Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs
por: Lau, Cedric, et al.
Publicado: (2023)

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial
por: van Rongen, Anne, et al.
Publicado: (2018)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
por: Darwich, A S, et al.
Publicado: (2013)

Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method
por: Calvier, E. A. M., et al.
Publicado: (2019)

A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics
por: Quinney, S K, et al.
Publicado: (2012)

Remifentanil versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial
por: de Hoogd, Sjoerd, et al.
Publicado: (2014)

Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats
por: Nontakham, Jannarin, et al.
Publicado: (2022)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study
por: Smit, Cornelis, et al.
Publicado: (2019)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis
por: Upadhyay, Parth J., et al.
Publicado: (2021)

Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function
por: Smit, Cornelis, et al.
Publicado: (2020)

Salivary Cortisol and Binge Eating Disorder in Obese Women After Surgery for Morbid Obesity
por: Larsen, Junilla K., et al.
Publicado: (2009)

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
por: Calvier, Elisa A. M., et al.
Publicado: (2016)

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
por: Adeloye, Temitope, et al.
Publicado: (2018)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39dckc1l8ne0msgg6dslrpfvoc